Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

Entrada Therapeutics, Inc. announced a new collaboration with the Myotonic Dystrophy Clinical Research Network supporting Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1.